Altoida

Executive Summary

Altoida is a Washington, D.C.-based digital health company that has developed the NeuroMarker Platform, a cutting-edge diagnostic tool combining neuroscience, machine learning, augmented reality, and sensor data to assess brain health. Founded in 2017 and building on two decades of research, the platform is initially focused on early detection of mild cognitive impairment (MCI) and Alzheimer's disease, with plans to expand into other central nervous system conditions. By moving beyond traditional pen-and-paper assessments, Altoida aims to provide objective, accessible, and continuous monitoring of neurological function, potentially enabling earlier intervention and better disease management. The company's technology is designed to be used in clinical settings and remotely, leveraging smartphones and tablets to deliver insights that are both transparent and measurable. Altoida operates in the rapidly growing digital diagnostics market, with Alzheimer's disease representing a significant unmet need for accurate, scalable screening tools. The company's platform has the potential to reduce diagnostic delays and improve clinical trial recruitment by identifying patients earlier. While still in a relatively early stage without disclosed funding or revenue, Altoida's innovative approach and strong scientific foundation position it as a promising player in neurology. Key upcoming catalysts include regulatory clearance, validation studies, and strategic partnerships that could accelerate commercialization and adoption.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) Clearance for NeuroMarker Platform in Alzheimer's60% success
• H1 2026Publication of Pivotal Validation Study Results70% success
• H2 2026Strategic Partnership with Major Pharmaceutical or Healthcare Provider50% success